Close menu

November 3rd, 2022 | 12:01 CET

BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?

  • Biotechnology
  • vaccine
  • Cancer
Photo credits:

BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    BioNTech: Full coffers and full pipeline

    mRNA technology is considered the key to fighting cancer. In Germany alone, almost half a million people develop cancer - every year. And the disease often ends fatally. In 2020, around 200,000 people died in Germany as a result. The figures illustrate how important a vaccine against the disease would be. The race for the first approval is on, and BioNTech is right in the middle of it. Thanks to the billions in profits from the COVID-19 vaccine, the Mainz-based company can go full throttle with development. And things are moving forward: BioNTech CEO Ugur Sahin expressed great confidence in an interview with the British BBC. He wants to offer the first cancer vaccines before 2030. During the pandemic, the Company not only earned a lot but learned a lot about vaccine development. And regulators have also learned more about mRNA, so approval processes should run more smoothly. Overall, the development pipeline at the Mainz-based company is full to bursting. One seasonal flu vaccine is in phase 3, 5 are in phase 2, 16 are in phase 1, and another 11 are in the preclinical phase. If BioNTech were to win the race - as it did with COVID-19 - for the cancer vaccine, quite different share price regions would probably be possible. However, this would require more newsflow, and this is not expected in the short term. Unlike the following company...

    Defence Therapeutics: Positive newsflow - when will the share react?

    Defence Therapeutics aims to revolutionize modern medicine with an unconventional approach. To this end, the biotech company has built a platform based on its patented Accum technology. The Accum method is designed to enable more efficient and effective vaccines by transporting vaccine antigens and antibody-drug conjugates in an intact form to the respective target cells. The Canadians' focus is on cancer and infectious diseases. Newsflow in recent weeks has been positive. First, the start of a new preclinical program for the treatment of lung cancer, including various types of malignant tumors of the upper and lower respiratory tract, was reported. The global market for lung cancer therapeutics alone is expected to grow more than 10% annually through 2029, reaching more than USD 54 billion. Interestingly, Defence Therapeutics' product is said to be easily ingested through the nose.

    The latest announcement from Defence Therapeutics is also interesting. The Company has initiated a new research and development program to use Accum technology to develop mRNA-based cancer vaccines. "By linking Accum to an mRNA molecule, we can ensure that the vaccine is not only delivered to the right section of the cell but also accumulates in large quantities to trigger an immune response, said Mr Plouffe, CEO of Defence Therapeutics. Initially, a program for an Accum mRNA vaccine against cancer has been initiated, targeting solid lymphomas. Subsequently, other research-based companies - BioNTech and Moderna, for example - will be able to use the Accum platform. The share has shown hardly any positive reaction in recent weeks. At EUR 1.28, it is trading just below the low for the year of EUR 1.03. To put this in perspective: just over a year ago, the stock was still trading above EUR 4. The market capitalization is around CAD 60 million.

    Bayer: More than 50% price potential?

    Bayer shares are currently in an uptrend. The downward trend that has been in place since May seems to have at least been broken. The share is currently trading at just over EUR 53. Analysts were optimistic ahead of the quarterly figures. According to them, the fundamental data in all three business areas of the Dax group are positive. Therefore, the analysts have renewed the price target of EUR 90 and the rating "Overweight". JPMorgan colleagues are also bullish on Bayer shares. They also say "Overweight" and trust the Bayer share to reach EUR 80. Credit Suisse is somewhat more reserved. Their analysts rate Bayer as "Neutral". However, the price target of EUR 66 is also still just under 25% above the current level. According to Credit Suisse, Bayer is one of the companies benefiting from a weak euro. And this should continue in the coming years.

    BioNTech is one of the promising mRNA players. Those who like it more speculative should look at Defence Therapeutics - the newsflow at least gives hope for higher prices. At Bayer, the glyphosate issue finally seems to be moving into the background.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.


    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.


    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.